Recursion Pharmaceuticals (NasdaqGS:RXRX) saw its stock price increase by 12% over the past week. This movement could be associated with several recent developments. The company announced a ...

Despite the current downward trend of RXRX, one should retain the stock for long-term gains due to the significant potential ...

Recursion announced that Namandje Bumpus, Ph.D, and Elaine Sun have been appointed to Recursion’s Board of Directors, effective as of March ...

Around the middle of February, shares of Recursion Pharmaceuticals bounded higher after the company reported phase 2 results ...

We recently published a list of 10 Firms Kick Off Monday Leading Gains. In this article, we are going to take a look at where Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) stands against other firms ...

Recursion is currently generating limited revenue through partnerships with larger pharmaceutical leaders like Merck and ...

Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating ...

Bullish option flow detected in Recursion Pharmaceuticals (RXRX) with 13,931 calls trading, 1.4x expected, and implied vol increasing over 13 ...

Explore why Recursion Pharmaceuticals' AI-driven drug discovery faces challenges in revenue growth, governance, and investor ...

Recursion Pharmaceuticals ( ($RXRX) ) has shared an update. On March 18, 2025, Recursion Pharmaceuticals announced the appointment of Dr. Namandjé ...

Learn more about whether Recursion Pharmaceuticals, Inc. or Zai Lab Limited is a better investment based on AAII's A+ ...

Learn more about whether Recursion Pharmaceuticals, Inc. or Veracyte, Inc. is a better investment based on AAII's A+ Investor ...